Regeneron Pharmaceuticals (NASDAQ:REGN) traded negative at $356.82. On an intraday basis, the price dropped -9.7 points or -2.65%. The composite uptick value was $104.26 million while the combined downtick value was $55.43. The net money flow was $48.82 million while the up/down ratio was not very comforting at 1.88. The shares on a weekly note has seen a change in share price of -4.09%.According to the trading data, the shares saw a block trade with $33.17 million in upticks and $8.92 million in downticks. The up/down ratio for the block was calculated to be 3.72. The net money flow for the block trade was 24.24.
Regeneron Pharmaceuticals, Inc. has lost 4.79% in the last five trading days and dropped 9.24% in the last 4 weeks. Regeneron Pharmaceuticals, Inc. has dropped 2.83% during the last 3-month period . Year-to-Date the stock performance stands at -34.75%.
Currently the company Insiders own 10.4% of Regeneron Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.67% . Institutional Investors own 75.17% of Regeneron Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.67%. . On the companys insider trading activities, Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, unloaded 1,000 shares at an average price of $396.64 on May 24, 2016. The total amount of the transaction was worth $396,640, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals (NASDAQ:REGN) witnessed a decline in the market cap on Friday as its shares dropped 3.36% or 12.31 points. After the session commenced at $367.31, the stock reached the higher end at $369.87 while it hit a low of $354. With the volume soaring to 1,164,253 shares, the last trade was called at $354.21. The company has a 52-week high of $605.9299. The company has a market cap of $37,220 million and there are 105,078,593 shares in outstanding. The 52-week low of the share price is $348.96.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.